Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications

Hepatology

Volumn 47, Issue 1, 2008, Pages 332-342

  Talwalkar, Jayant A ^a   Yin, Meng ^a   Fidler, Jeff L ^a   Sanderson, Schuyler O ^a   Kamath, Patrick S ^a   Ehman, Richard L ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISEASE MARKER; ELASTOGRAPHY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING;

EID: 38649113882     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21972     Document Type: Review

References (77)

1. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. HEPATOLOGY 2002;36:227-242.
2. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006;101:2128-138.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
4. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058.
5. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12:3682-3694.
6. Talwalkar JA. Shall we bury the sword? Magnetic resonance imaging of hepatic fibrosis. Gastroenterology 2006;131:1669-1671.
7. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906.
8. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
10. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
11. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006;55:569-578.
12. O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 2000;114:712-718.
13. Lee HS, Shun CT, Chiou LL, Chen CH, Huang GT, Sheu JC. Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: emphasis on sampling variability. J Gastroenterol Hepatol 2005;20:1109-1114.
14. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-173.
15. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99:1160-1174.
16. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44:462-474.
17. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686-693.
18. Hussain SM, Semelka RC. Hepatic imaging: comparison of modalities, Radiol Clin North Am 2005;43:929-947.
19. Lim AK, Patel N, Eckersley RJ, Kuo YT, Goldin RD, Thomas HC, et al. Can Doppler sonography grade the severity of hepatitis C-related liver disease? AJR Am J Roentgenol 2005;184:1848-1853.
20. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection - analysis of 300 cases. Radiology 2003;227:89-94.
21. Aube C, Winkfield B, Oberti F, Vuillemin E, Rousselet MC, Caron C, et al. New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. Eur J Gastroenterol Hepatol 2004;16:743-51.
22. Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005;54:128-133.
23. Cohen EI, Wilck EJ, Shapiro RS. Hepatic imaging in the 21st century. Semin Liver Dis 2006;26:363-372.
24. Numminen K, Tervahartiala P, Halavaara J, Isoniemi H, Hockerstedt K. Non-invasive diagnosis of liver cirrhosis: magnetic resonance imaging presents special features. Scand J Gastroenterol 2005;40:76-82.
25. Awaya H, Mitchell DG, Kamishima T, Holland G, Ito K, Matsumoto T. Cirrhosis: modified caudate-right lobe ratio. Radiology 2002;224:769-774.
26. Ito K, Mitchell DG, Gabata T, Hussain SM. Expanded gallbladder fossa: simple MR imaging sign of cirrhosis. Radiology 1999;211:723-726.
27. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics 2006;26:1621-1636.
28. Semelka RC, Chung JJ, Hussain SM, Marcos HB, Woosley JT. Chronic hepatitis: correlation of early patchy and late linear enhancement patterns on gadolinium-enhanced MR images with histopathology initial experience. J Magn Reson Imaging 2001;13:385-391.
29. Elizondo G, Weissleder R, Stark DD, Guerra J, Garza J, Fretz CJ, et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801.
30. Yamashita Y, Yamamoto H, Hirai A, Yoshimatsu S, Baba Y, Takahashi M. MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: influence of liver dysfunction and parenchymal pathology. Abdom Imaging 1996;21:318-323.
31. Lucidarme O, Baleston F, Cadi M, Bellin MF, Charlotte F, Ratziu V, et al. Non-invasive detection of liver fibrosis: is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur Radiol 2003;13:467-474.
32. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006;239:425-437.
33. Lee VS. Science to practice: can MR imaging replace liver biopsy for the diagnosis of early fibrosis? Radiology 2006;239:309-310.
34. Hundt W, Petsch R, Helmberger T, Reiser M. Signal changes in liver and spleen after Endorem administration in patients with and without liver cirrhosis. Eur Radiol 2000;10:409-416.
35. Tanimoto A, Yuasa Y, Shinmoto H, Jinzaki M, Imai Y, Okuda S, et al. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function. Radiology 2002;222:661-666.
36. Naganawa S, Kawai H, Fukatsu H, Sakurai Y, Aoki I, Miura S, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005;4:175-186.
37. Aube C, Racineux PX, Lebigot J, Oberti F, Croquet V, Argaud C, et al. Diagnosis and quantification of hepatic fibrosis with diffusion weighted MR imaging: preliminary results. J Radiol 2004;85:301-306.
38. Annet L, Peeters F, Abarca-Quinones J, Leclercq I, Moulin P, Van Beers BE. Assessment of diffusion-weighted MR imaging in liver fibrosis. J Magn Reson Imaging 2007;25:122-128.
39. Girometti R, Furlan A, Bazzocchi M, Soldano F, Isola M, Toniutto P, et al. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med 2007;112:394-408.
40. Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005;22:80-85.
41. Boulanger Y, Amara M, Lepanto L, Beaudoin G, Nguyen BN, Allaire G, et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients. NMR Biomed 2003;16:132-136.
42. Taouli B, Martin AJ, Qayyum A, Merriman RB, Vigneron D, Yeh BM, et al. Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol 2004;183:677-680.
43. Jalan R, Taylor-Robinson SD, Hodgson HJF. In vivo hepatic magnetic resonance spectroscopy: clinical or research tool ? J Hepatol 1999;25:414-424.
44. Khan SA, Cox IJ, Hamilton G, Thomas HC, Taylor-Robinson SD. In vivo and in vitro nuclear magnetic resonance spectroscopy as a tool for investigating hepatobiliary disease: a review of H and P MRS applications. Liver Int 2005;25:273-281.
45. Solga SF, Horska A, Clark JM, Diehl AM. Hepatic 31P magnetic resonance spectroscopy: a hepatologist's user guide. Liver Int 2005;25:490-500.
46. Cox IJ. Development and applications of in vivo clinical magnetic resonance spectroscopy. Prog Biophys Mol Biol 1996;65:45-81.
47. Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clin Med 2001;1:54-60.
48. 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver 1997;17:198-209.
49. 31P MRS study of patients with liver cirrhosis: progress towards a non-invasive assessment of disease severity. NMR Biomed 1993;6:168-172.
50. Menon D K, Sargentoni J, Taylor-Robinson SD, Bell JD, Cox IJ, Bryant DJ, et al. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. HEPATOLOGY 1995;21:417-427.
51. 31P magnetic resoance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. Gut 1996;39:141-146.
52. Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. HEPATOLOGY 2003;37:788-794.
53. van Wassenaer-van Hall HN, van der Grand J, van Hattum J, Kooijman C, Hoogenraad TU, Mali WP. 31P magnetic resonance spectroscopy of the liver: correlation with standardized serum, clinical, and histological changes in diffuse liver disease. HEPATOLOGY 1995;21:443-449.
54. Cho SG, Kim MY, Kim HJ, Kim YS, Choi W, Shin SH, et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001;221:740-746.
55. Schlemmer HP, Sawatzki T, Sammet S, Dornacher I, Bachert P, van Kaick G, et al. Hepatic phospholipids in alcoholic liver disease assessed by proton-de-coupled 31P magnetic resonance spectroscopy. J Hepatol 2005;42:752-759.
56. Greenleaf JF, Fatemi M, Insana M. Selected methods for imaging elastic properties of biological tissues. Annu Rev Biomed Eng 2003;5:57-78.
57. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005;39:S158-S161.
58. Manduca A, Oliphant TE, Dresner MA, Mahowald JL, Kruse SA, Amromin E, et al. Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal 2001;5:237-254.
59. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.
60. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. HEPATOLOGY 2005;41:48-54.
61. Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. HEPATOLOGY 2006;43:1118-1124.
62. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-408.
63. Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 1995;269:1854-1857.
64. Kruse SA, Smith JA, Lawrence AJ, Dresner MA, Manduca A, Greenleaf JF, et al. Tissue characterization using magnetic resonance elastography: preliminary results. Phys Med Biol 2000;45:1579-1590.
65. Huwart L, Peeters F, Sinkus R, Annet L, Salameh N, ter Beek LC, et al. Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed 2006;19:173-179.
66. Rouviere O, Yin M, Dresner MA, Rossman PJ, Burgart LJ, Fidler JL, et al. MR elastography of the liver: preliminary results. Radiology 2006;240:440-448.
67. Klatt D, Asbach P, Rump J, Papazoglou S, Somasundaram R, Modrow J, et al. In vivo determination of hepatic stiffness using steady-state free precision magnetic resonance elastography. Invest Radiol 2006;41:841-848.
68. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastro Hep 2007;5:1207-1213.
69. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Ann Intern Med 2003;138:40-44.
70. Winkfield B, Aube C, Burtin P, Cales P. Inter-observer and intra-observer variability in hepatology. Eur J Gastroenterol Hepatol 2003;15:959-966.
71. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 2006;44:111-117.
72. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-1624.
73. Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12:1791-1798.
74. Talwalkar JA. Functional hepatic imaging and disease recurrence after liver transplantation. Liver Transpl 2006;12:1744-1746.
75. Hyslop WB, Semelka RC. Future directions in body magnetic resonance imaging. Top Magn Reson Imaging 2005;16:3-14.
76. Cobbold JF, Wylezinska M, Cunningham C, Crossey ME, Thomas HC, Cox IJ, et al. Non-invasive evaluation of hepatic fibrosis using magnetic resonance and ultrasound techniques. Gut 2006;55:1670.
77. Friedman SL, Bansal MB. Reversal of hepatic fibrosis: fact or fantasy? HEPATOLOGY 2006;43(Suppl):S82-S88.